Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with world-class lymphoma experts: Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, and Caron Jacobson, MD, from the Dana-Farber Cancer Institute, Boston, MA, on key updates from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. The group explores the use of CAR T-cell therapy, considering the hurdles and benefits, and discusses the realm of precision medicine in this field.